منابع مشابه
Radioimmunotherapy for Non-Hodgkin's Lymphoma.
Non-Hodgkin's lymphoma (NHL) is the most common hematological malignancy in the United States with a rapidly increasing incidence. Most follicular NHL is indolent but incurable, whereas the more aggressive varieties do respond to therapy. Most patients with follicular NHL who transform to an aggressive NHL are very difficult to treat successfully. Treatment options have included chemotherapy, r...
متن کاملSome like it hot: lymphoma radioimmunotherapy.
Radioimmunotherapy (RIT or RAIT) dates back more than 2 decades and has evolved to encompass a variety of tumorseeking antibodies in various forms, with different radionuclides, different delivery methods, for different clinical indications (usually advanced disease).1 Although selective antibody targeting has been demonstrated, the radiation doses delivered have been insufficient to markedly i...
متن کاملIodine-131 Rituximab Radioimmunotherapy: Durable Control of Follicular Lymphoma
Aims: We evaluated the response and toxicity, after long-term follow up of Iodine-131 rituximab radioimmunotherapy in patients with follicular lymphoma under the routine clinical care of a single hematologist over a period of 12 years. Materials and methods: Patients received 131I-rituximab radioimmunotherapy according to a standard, personalized dosimetry protocol predicated upon a prescribed ...
متن کاملRadioimmunotherapy in the treatment of non-Hodgkin's lymphoma.
When the body detects something that can cause disease, like a virus or bacteria or a cancer cell, the immune system sends out specific cells to try to destroy the invader. Antibodies connect to harmful molecules. The antibodies act as flags for other immune system cells to attack the harmful molecule. Monoclonal antibodies are made in a lab and are engineered to attach to very specific targets...
متن کاملRadioimmunotherapy for lymphoma - analysis of clinical trials and treatment algorithms.
Ibritumomab, an (90)Yttrium ((90)Y) labelled radioimmunoconjugate, is registered in Europe to treat follicular lymphomas. Its mode of action combines the selectivity of monoclonal antibodies with the efficiency of radiotherapy, making it a unique and useful therapeutic agent. This paper is for haemato-oncologists with a decent practice in lymphoma therapy, who have not yet used ibritumomab them...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Arhiv za onkologiju
سال: 2012
ISSN: 0354-7310,1450-9520
DOI: 10.2298/aoo1204136g